What we're reading, February 2, 2016: Aetna joins other major insurers raising concerns over the Affordable Care Act's insurance exchanges; Sanofi announces plans to develop a Zika vaccine; and Martin Shkreli expected to testify despite dismissing the subpoena.
Aetna has now joined other major insurers who have raised concerns over the sustainability of the Affordable Care Act’s insurance exchanges. The New York Times reported that Aetna has struggled with consumers signing up outside of the open enrollment period. However, CMS recently dropped several special enrollment periods. Aetna is operating in 15 state-based exchanges and has enrolled 750,000 people, but lost more than $100 million on its exchange business in 2015.
As the World Health Organization declared the Zika virus a public health emergency on an international scale, Sanofi announced that it has launched a project to develop a vaccine for the virus, which has been linked to multiple birth defects in Brazil, according to Reuters. Small biotech companies and academic institutions also have plans to develop a vaccine, and GlaxoSmithKline is concluding feasibility studies on its vaccine technology.
Although he dismissed the subpoena, ex-Turing Pharmaceutical CEO Martin Shkreli is expected to appear on Thursday to testify before the House Oversight and Government Committee for the hearing “Developments in the Prescription Drug Market,” reported Roll Call. Other pharmaceutical representatives from Valeant Pharmaceuticals International, Inc, and the Pharmaceutical Care Management Association are expected to testify as well on Thursday.
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More